At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
News|Articles|November 9, 2026
Top 3 Poster Takeaways in Liver Cancer Care From The Liver Meeting 2026
Author(s)Cancer Network Staff
Fact checked by: Roman Fabbricatore, Russ Conroy
Posters at The Liver Meeting 2026 refined HCC risk stratification in hepatitis delta or after HCV cure and examined ICI liver injury in cirrhosis.
Advertisement
Advertisement
At The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), held November 5-9 in Denver, Colorado, poster presentations addressed hepatocellular carcinoma (HCC) risk across several high-risk populations. Investigators evaluated established risk scores in patients with chronic hepatitis delta (CHD) receiving long-term bulevirtide-gmod (Hepcludex), examined how cardiometabolic risk factors shape HCC risk after hepatitis C virus (HCV) cure, and assessed liver injury after immune checkpoint inhibitor (ICI) initiation in patients with cirrhosis. Two of the posters were designated Posters of Distinction.
Related to this article
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Pierre Gholam, MD, discussed how navigation, molecular profiling, and hub-and-spoke models can help liver tumor boards turn recommendations into care.
Neil Mehta, MD, and Laura Kulik, MD, discussed patient selection, washout timing, and posttransplant monitoring for immunotherapy before liver transplant.
Advertisement
Advertisement